Creatine: The Body's Universal Energy Currency for Muscle, Brain, and Longevity

Creatine is one of the most extensively researched and consistently validated supplements in the history of nutritional science. Far from being merely a bodybuilding aid, creatine is an endogenous compound synthesized from the amino acids glycine, arginine, and methionine in the liver, kidneys, and pancreas. It serves as the body's most immediate energy buffer, regenerating ATP (adenosine triphosphate) at rates far exceeding any other metabolic pathway. Approximately 95% of the body's creatine is stored in skeletal muscle as phosphocreatine, with the remaining 5% distributed in the brain, heart, kidneys, and testes. With over 685 clinical trials confirming its safety and efficacy, creatine monohydrate stands as the single most effective legal ergogenic supplement available, while emerging research reveals profound benefits for brain health, aging, immune function, and disease prevention that extend far beyond the gym.

Table of Contents

1. History and Discovery
2. Mechanism of Action: The Phosphocreatine Energy System
3. Muscle Performance and Athletic Enhancement
4. Brain Health and Cognitive Function
5. Cardiovascular Health
6. Anti-Aging and Sarcopenia
7. Immune Function and Cancer Research
8. Blood Sugar Regulation
9. Women's Health
10. Bone Health
11. Mental Health and Depression
12. Creatine Deficiency Syndromes
13. Vegetarians and Vegans
14. Dietary Sources
15. Supplementation: Forms, Dosing, and Protocols
16. Safety and the Kidney Myth
17. Key References

1. History and Discovery

The story of creatine begins in 1832, when French chemist Michel Eugène Chevreul first isolated a new organic compound from the water-extract of skeletal muscle, naming it creatine from the Greek word kreas, meaning meat. In 1847, the renowned German chemist Justus von Liebig chemically identified creatine as methylguanidino-acetic acid and made the prescient observation that wild animals contained significantly more muscle creatine than their domesticated counterparts, suggesting a link between physical activity and creatine accumulation.

The discovery of phosphocreatine in 1927 revealed how creatine actually functions as an energy buffer within muscle tissue. However, it was not until 1992 that the modern era of creatine supplementation began with a landmark study by Roger C. Harris at the Karolinska Institute in Sweden. Harris demonstrated in Clinical Science that supplementing with 5 grams of creatine monohydrate four to six times daily for just two days could increase total creatine content of the quadriceps femoris muscle by up to 50% in some subjects. That same year, gold medal sprinter Linford Christie and 400-meter hurdles champion Sally Gunnell reportedly used creatine at the 1992 Barcelona Olympics, catapulting the supplement into public awareness.

In 1996, Eric Hultman and colleagues at the Karolinska Institute established the loading and maintenance dosing protocol still used today, published in the Journal of Applied Physiology. Since then, creatine has become the most studied sports supplement in history, with the International Society of Sports Nutrition issuing comprehensive position stands in 2007 and 2017 affirming its safety and efficacy, and a 2025 analysis of 685 clinical trials confirming no significant differences in side effect rates between creatine and placebo groups.

2. Mechanism of Action: The Phosphocreatine Energy System

Every cell in the body runs on ATP, but the cell's ATP supply is extremely limited, sufficient for only about 1-2 seconds of maximal effort. The phosphocreatine (PCr) system provides the fastest mechanism for regenerating ATP, operating at rates ten times faster than oxidative phosphorylation and three times faster than glycolysis.

The enzyme creatine kinase catalyzes the reversible transfer of a phosphate group from phosphocreatine to ADP, rapidly regenerating ATP:

Phosphocreatine + ADP → Creatine + ATP

This reaction occurs in milliseconds and does not require oxygen, making the PCr system the dominant energy pathway during the first 6-10 seconds of maximal-intensity activity. Phosphocreatine contributes approximately 50% of ATP resynthesis during the first of repeated 6-second sprints. By increasing intramuscular phosphocreatine stores through supplementation (typically by 20-40%), the body gains a larger energy reserve for high-intensity efforts, faster recovery between bouts, and enhanced capacity for repeated explosive movements.

Critically, the creatine kinase system functions not only as a temporal energy buffer but also as a spatial energy shuttle. Mitochondrial creatine kinase (Mi-CK) regenerates phosphocreatine at the inner mitochondrial membrane, while cytosolic creatine kinase regenerates ATP at the sites of energy consumption (myofibrils, ion pumps, membrane receptors). This phosphocreatine shuttle efficiently transports high-energy phosphate groups from the mitochondria to wherever the cell needs them most.

3. Muscle Performance and Athletic Enhancement

The evidence for creatine's ergogenic effects is overwhelming and has been confirmed across hundreds of studies. A meta-analysis by Rawson and Volek (2003) in the Journal of Strength and Conditioning Research, reviewing 22 studies, found that creatine combined with resistance training produced an 8% greater increase in strength (20% vs. 12% for placebo) and a 14% greater increase in weightlifting performance (26% vs. 12%).

Jeff Volek at Penn State University conducted a pivotal 12-week periodized resistance training study published in Medicine & Science in Sports & Exercise (1999). The creatine group achieved a 24% increase in bench press (vs. 16% placebo) and a 32% increase in squat (vs. 24% placebo). Fat-free mass increased by 6.3% in the creatine group versus 3.1% in placebo. Remarkably, muscle fiber cross-sectional area increased by 35% for Type I fibers (vs. 11% placebo), 36% for Type IIA fibers (vs. 15% placebo), and 35% for Type IIAB fibers (vs. 6% placebo).

A 2022 meta-analysis by Delpino, Forbes, and Candow in Nutrition, pooling 35 studies and 1,192 participants, confirmed that creatine combined with resistance training increased lean body mass by an average of 1.1 kg regardless of age. Males gained 1.46 kg of lean mass on average. These effects are consistent, reproducible, and significant across diverse populations.

4. Brain Health and Cognitive Function

The brain represents only 2% of body mass but consumes approximately 20% of the body's total energy production. This extraordinary metabolic demand makes the brain highly sensitive to energy supply disruptions and potentially highly responsive to creatine supplementation.

The foundational study on creatine and cognition was conducted by Caroline Rae at the University of Sydney (2003), published in Proceedings of the Royal Society of London, Series B. In a double-blind, placebo-controlled crossover trial, 45 vegetarian participants receiving 5 g/day of creatine for six weeks showed significant improvements in both working memory (backward digit span improved from approximately 7 to 8.5 digits) and fluid intelligence on Raven's Advanced Progressive Matrices (p < 0.0001).

Terry McMorris at the University of Chichester demonstrated that creatine loading (20 g/day for 7 days) protected cognitive performance during sleep deprivation. In his 2006 study in Psychopharmacology, the creatine group showed significantly less decline in choice reaction time, random movement generation, balance, and mood state after 24 hours without sleep. A follow-up in Physiology & Behavior (2007) extended these findings to 36-hour sleep deprivation.

In a groundbreaking 2023 publication in eLife, Yi Rao at Peking University presented evidence that creatine may function as a neurotransmitter in the central nervous system. Creatine was found in synaptic vesicles at concentrations higher than acetylcholine and serotonin, and electrophysiological evidence showed it inhibits a fraction of pyramidal neurons in the neocortex. If confirmed, this would fundamentally reshape our understanding of creatine's role in brain function.

Most recently, the CABA trial (2025) at the University of Kansas Medical Center, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, became the first pilot trial of creatine in Alzheimer's disease. Twenty patients receiving 20 g/day for 8 weeks showed increased brain creatine levels and moderate improvements in working memory and executive function.

5. Cardiovascular Health

The heart is one of the most metabolically active organs in the body, and the creatine-phosphocreatine system is essential for cardiac energy homeostasis. Reduced myocardial creatine levels have been documented in heart failure, and restoring creatine availability shows therapeutic promise.

Gordon et al. (1995) conducted a double-blind, placebo-controlled trial in 17 chronic heart failure patients, published in the European Heart Journal. After receiving creatine 20 g/day for 10 days, patients showed a 17% increase in skeletal muscle creatine, a 12% increase in phosphocreatine, a 21% improvement in one-legged exercise performance, and a 10% improvement in two-legged performance.

Andrews et al. (1998), also in the European Heart Journal, demonstrated that creatine supplementation in congestive heart failure patients augmented skeletal muscle endurance and attenuated the abnormal metabolic responses to exercise that characterize heart failure. Animal models further demonstrate that creatine supplementation can lower homocysteine levels, reduce arterial stiffness, and decrease markers of systemic inflammation including TNF-alpha and C-reactive protein.

6. Anti-Aging and Sarcopenia

Sarcopenia, the age-related loss of muscle mass and function, is one of the most significant contributors to disability, falls, fractures, and loss of independence in aging populations. Muscle mass begins declining at approximately 3-8% per decade after age 30, accelerating after age 60. Creatine supplementation, particularly when combined with resistance training, offers one of the most effective interventions for combating this decline.

A meta-analysis by Chilibeck, Kaviani, Candow, and Zello (2017) in the Open Access Journal of Sports Medicine found that creatine combined with resistance training in older adults increased lean tissue mass and both upper and lower body strength significantly more than resistance training alone. A 2025 review in the Journal of the International Society of Sports Nutrition outlined how creatine may address multiple hallmarks of aging including mitochondrial dysfunction, cellular senescence, oxidative stress, and telomere attrition.

Research published in Experimental Gerontology (2025) explored creatine's influence on key senescence signaling pathways, describing mechanisms through which enhanced cellular energy homeostasis and mitigated oxidative stress may slow biological aging at the cellular level.

7. Immune Function and Cancer Research

One of the most exciting frontiers in creatine research is its role in immune function and anti-tumor immunity. In a landmark 2019 study published in the Journal of Experimental Medicine, Lili Yang at UCLA demonstrated that creatine acts as a "molecular battery" for CD8 T cells (killer T cells), powering their ability to destroy cancer cells.

Yang's research showed that T cells deficient in the creatine transporter gene (CrT/Slc6a8) had severely impaired anti-tumor responses. Critically, oral creatine supplementation at doses comparable to those used by human athletes suppressed both skin and colon cancer tumor growth in mice. When combined with PD-1/PD-L1 checkpoint inhibitor immunotherapy, creatine showed synergistic tumor suppression. A 2023 study in Frontiers in Immunology extended these findings, showing creatine enhances anti-tumor immunity by promoting ATP production in macrophages within the tumor microenvironment.

Epidemiological data from NHANES 2007-2018, published in Frontiers in Nutrition (2024), found that higher dietary creatine intake was associated with lower cancer risk in U.S. adults: approximately a 1% reduction in cancer risk for every additional milligram of creatine per kilogram of body mass consumed daily. A clinical trial protocol (CREATINE-52) examining creatine supplementation to preserve muscle mass and attenuate cancer progression was registered in BMC Cancer in 2024.

8. Blood Sugar Regulation

Bruno Gualano at the University of São Paulo, Brazil, conducted the most significant study on creatine and type 2 diabetes. Published in Medicine & Science in Sports & Exercise (2011), this 12-week randomized, double-blind, placebo-controlled trial enrolled 25 type 2 diabetic patients. The creatine group (5 g/day with exercise) saw HbA1c decrease from 7.4% to 6.4%, compared to 7.5% to 7.6% in the placebo group (p = 0.004). The creatine group also showed decreased glycemia at 0, 30, and 60 minutes during a meal tolerance test and, critically, increased GLUT-4 translocation to the cell surface, the mechanism by which glucose enters muscle cells.

The proposed mechanisms include increased beta-cell insulin secretion, improved AMPK-alpha activation driving GLUT-4 translocation, and enhanced cellular water retention triggering osmosensing gene expression. While a systematic review by Ashtary-Larky et al. (2022) in Clinical Nutrition ESPEN noted the need for larger trials, Gualano's results represent a compelling proof of concept for creatine as an adjunct therapy in type 2 diabetes management.

9. Women's Health

Despite being widely perceived as a male-oriented supplement, creatine may be especially important for women. Females have 70-80% lower endogenous creatine stores than males, creating a larger potential for benefit from supplementation. A comprehensive review by Smith-Ryan et al. (2021) in Nutrients examined creatine across the female lifespan.

An analysis of 4,522 women from NHANES 2017-2020, published by Ostojic et al. (2024) in Food Science & Nutrition, found that women consuming 13 mg or more of dietary creatine per kilogram of body mass daily had significantly lower risk of oligomenorrhea, pelvic infection, hysterectomy, and oophorectomy.

The CONCRET-MENOPA trial (2026), published in the Journal of the American Nutrition Association, studied 36 perimenopausal and menopausal women. Medium-dose creatine hydrochloride (1,500 mg/day) produced superior reaction time improvement, a 16.4% increase in frontal brain creatine (vs. 0.9% placebo, p < 0.01), and improved lipid profiles. All creatine groups showed significant reductions in fatigue and concentration difficulties.

Animal research by Ellery and Dickinson at Monash University and the Hudson Institute in Australia has shown that maternal creatine supplementation during pregnancy increases creatine and phosphocreatine in fetal tissues and improves survival and postnatal growth after birth hypoxia, opening a potential avenue for fetal neuroprotection.

10. Bone Health

Darren Candow at the University of Regina conducted a landmark 2-year randomized controlled trial with 237 postmenopausal women, published in Medicine & Science in Sports & Exercise (2023). While creatine supplementation during resistance training and walking did not significantly affect bone mineral density, it significantly maintained bone bending strength (section modulus) and cortical stability under compression (buckling ratio) at the femoral neck. Creatine also increased lean tissue mass versus placebo, which indirectly supports bone health through greater mechanical loading.

A 2025 review in Osteoporosis International concluded that current evidence is insufficient to recommend creatine as a standalone therapy for osteoporosis, but its benefits for bone geometry and structural integrity when combined with resistance exercise are promising and warrant further investigation.

11. Mental Health and Depression

The most significant study on creatine and depression was conducted by In Kyoon Lyoo at Seoul National University and the University of Utah. Published in the American Journal of Psychiatry (2012), this randomized, double-blind, placebo-controlled trial enrolled 52 women with major depressive disorder (MDD). Participants received escitalopram (an SSRI) plus either creatine (5 g/day) or placebo for 8 weeks.

The results were striking: the creatine group showed significant improvement as early as week 2, with an odds ratio of 11.68 for treatment response compared to placebo. By week 8, the odds ratio remained at 6.92. Phosphorus-31 magnetic resonance spectroscopy showed that increased cerebral phosphocreatine levels correlated directly with symptom improvement, supporting the bioenergetic mechanism of action. The implications are profound: creatine may accelerate and enhance the antidepressant response to SSRIs, potentially reducing the dangerous lag period during which patients remain symptomatic and at risk.

12. Creatine Deficiency Syndromes

Three rare inborn errors of creatine metabolism dramatically illustrate the essential nature of this compound for human health:

• GAMT deficiency (guanidinoacetate methyltransferase): Approximately 130 individuals reported worldwide. Presents with severe global developmental delay, intellectual disability, epilepsy (in over 70% of cases), and behavioral disorders. Treated with oral creatine monohydrate combined with L-ornithine and an arginine-restricted diet. Patients treated before 9 months of age can achieve normal or near-normal development.
• AGAT deficiency (L-arginine:glycine amidinotransferase): The rarest of the three syndromes. Responds well to oral creatine supplementation.
• SLC6A8/CRTR deficiency (creatine transporter): X-linked and the most common creatine deficiency syndrome. Creatine supplementation is ineffective because the transporter needed to move creatine into brain cells is defective. Cyclocreatine, a creatine analog, is the most promising experimental treatment.

All three syndromes are diagnosable via urinary guanidinoacetate levels and brain magnetic resonance spectroscopy showing absent or severely reduced cerebral creatine. These conditions powerfully demonstrate what happens when the brain and body are deprived of adequate creatine, reinforcing the importance of maintaining sufficient creatine status throughout life.

13. Vegetarians and Vegans

Because creatine is found almost exclusively in animal-derived foods, vegetarians and vegans have significantly lower baseline creatine stores. Vegetarians average approximately 100 mmol/kg of dry muscle creatine compared to 120 mmol/kg in omnivores, and brain creatine levels are also lower in those who do not consume meat.

Benton and Donohoe (2011), published in the British Journal of Nutrition, found that creatine supplementation resulted in better memory performance in vegetarians but not in omnivores, despite no baseline cognitive differences between groups. This suggests that vegetarians have a greater capacity for cognitive improvement from supplementation due to their lower starting levels. Similarly, Burke et al. reported greater increases in muscle phosphocreatine after creatine supplementation in vegetarian participants compared to omnivores.

A 2025 narrative review in Nutrients emphasized that plant-based eaters may particularly benefit from creatine supplementation given their lower baseline stores and consistently greater response magnitude across both physical and cognitive outcomes.

14. Dietary Sources

The body synthesizes approximately 1-2 grams of creatine per day endogenously. An additional 1-2 grams can be obtained from an omnivorous diet. The richest dietary sources include:

• Herring: 6.5-10 g per kg
• Salmon: 4.5 g per kg
• Beef: 4.5 g per kg
• Pork: 5.0 g per kg
• Tuna: 4.0 g per kg
• Cod: 3.0 g per kg
• Milk: 0.1 g per liter

Cooking reduces creatine content by approximately 20-30% depending on method and duration. Given that achieving supplemental doses (3-5 g/day) through food alone would require consuming roughly 1 kg of raw meat or fish daily, supplementation with creatine monohydrate is the most practical approach for those seeking optimal creatine status.

15. Supplementation: Forms, Dosing, and Protocols

Loading Protocol (Fastest Saturation)

20-25 g/day (0.3 g/kg body weight), divided into 4-5 doses of 5 g each, for 5-7 days. This protocol, established by Hultman et al. (1996) in the Journal of Applied Physiology, saturates muscle creatine stores within one week, raising intramuscular creatine content by 20-40%.

Maintenance Protocol

3-5 g/day (0.03 g/kg body weight) indefinitely. Without a loading phase, this dose achieves the same saturation over approximately 3-4 weeks. Hultman et al. showed that 3 g/day over 28 days produced the same ~20% increase as the loading protocol.

Timing

Post-exercise supplementation has shown slightly greater benefits for body composition compared with pre-exercise in some studies. However, consistency of daily intake matters far more than precise timing.

Forms of Creatine

• Creatine monohydrate: The gold standard. Most extensively studied, most cost-effective, and most bioavailable form. The ISSN position stand explicitly states that no other form of creatine has been shown to be superior to creatine monohydrate.
• Micronized creatine monohydrate: Same compound with smaller particle size for improved mixability. No difference in efficacy.
• Creatine hydrochloride (HCl): More water-soluble, may be better tolerated at lower doses. Used in the CONCRET-MENOPA trial at 750-1,500 mg/day.
• Buffered creatine (Kre-Alkalyn): No evidence of superiority over monohydrate.
• Creatine ethyl ester: Actually shown to be inferior to monohydrate due to rapid degradation to creatinine.

16. Safety and the Kidney Myth

The persistent myth that creatine damages the kidneys has been thoroughly debunked by decades of research. Jacques Poortmans at the Free University of Brussels conducted the definitive studies. In 1999, he compared renal function in national and international athletes using creatine (1-80 g/day for 10-60 months) with non-users and found no significant differences in any marker of renal function. A 2005 follow-up with 20 healthy young men supplementing 21 g/day for 14 days confirmed no signs of renal impairment.

A 2025 systematic review and meta-analysis in BMC Nephrology confirmed that creatine supplementation causes a modest, transient increase in serum creatinine (a normal metabolic byproduct, not a marker of damage), with no significant changes in GFR (glomerular filtration rate), indicating fully preserved kidney function. The origin of the kidney myth lies in the fact that creatinine (a breakdown product of creatine) is used as a proxy for kidney function in standard blood tests. When creatine intake increases, creatinine levels rise proportionally, which can be misinterpreted as kidney damage by clinicians unfamiliar with the patient's supplementation status.

Richard B. Kreider at Texas A&M University, lead author of the ISSN position stands and author of over 300 peer-reviewed articles on creatine, published a comprehensive 2025 analysis of 685 clinical trials in the Journal of the International Society of Sports Nutrition. The analysis found no significant differences in the rate of side effects between creatine and placebo groups. The ISSN position stand states unequivocally: "No scientific evidence supports that short- or long-term supplementation (up to 30 g/day for 5 years) with creatine monohydrate causes any harmful side effects."

17. Key References

• Harris RC, Söderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clinical Science. 1992;83(3):367-374.
• Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. Journal of Applied Physiology. 1996;81(1):232-237.
• Volek JS, Duncan ND, Mazzetti SA, et al. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. Medicine & Science in Sports & Exercise. 1999;31(8):1147-1156.
• Rawson ES, Volek JS. Effects of creatine supplementation and resistance training on muscle strength and weightlifting performance. Journal of Strength and Conditioning Research. 2003;17(4):822-831.
• Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance. Proceedings of the Royal Society of London, Series B. 2003;270(1529):2147-2150.
• McMorris T, Harris RC, Swain J, et al. Effect of creatine supplementation and sleep deprivation on cognitive psychomotor performance. Psychopharmacology. 2006;185(1):93-103.
• Sakellaris G, Kotsiou M, Tamiolaki M, et al. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration. Journal of Trauma. 2006;61(2):322-329.
• Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. American Journal of Psychiatry. 2012;169(9):937-945.
• Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18.
• Yang L, et al. Creatine uptake regulates CD8 T cell antitumor immunity. Journal of Experimental Medicine. 2019;216(12):2869-2882.
• Gualano B, de Salles Painelli V, Roschel H, et al. Creatine in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Medicine & Science in Sports & Exercise. 2011;43(5):770-778.
• Delpino FM, Figueiredo LM, Forbes SC, Candow DG, Santos HO. Influence of age, sex, and type of exercise on the efficacy of creatine supplementation on lean body mass. Nutrition. 2022;103-104:111791.
• Rao Y, et al. Suggestion of creatine as a new neurotransmitter. eLife. 2023;12:e89317.
• Candow DG, et al. Creatine supplementation for postmenopausal bone health: a 2-year RCT. Medicine & Science in Sports & Exercise. 2023;55(10):1750-1761.
• Gordji-Nejad A, et al. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Scientific Reports. 2024;14:4937.
• Kreider RB, et al. Comprehensive analysis of 685 clinical trials on creatine safety. Journal of the International Society of Sports Nutrition. 2025;22(1).
• Smith CD, et al. CABA pilot trial: creatine in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025.

Back to Table of Contents